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Urinary tract obstruction leads to obstructive nephropathy, 
which in turn, frequently results in renal failure. Congenital 
urinary tract obstruction can be traced back to errors during the 
organogenesis of the urinary system. A fundamental understanding 
of the causes of urinary tract obstruction and the developmental 
processes involved are critical for improving the diagnostic and 
therapeutic strategies for this disease. A number of laboratories, 
including ours, have been using genetically engineered and sponta-
neously occurring mouse models to study the primary causes and 
the pathogenesis of urinary tract obstruction. These studies have 
shown that urinary tract obstruction is a very heterogeneous disease 
that can be caused by a diverse set of factors targeting multiple 
levels of the urinary system. Accumulating evidence also indicates 
that the development of the urinary tract requires the integration 
of progenitor cells of diverse embryonic origins, leading to the 
formation of multiple junctions prone to developmental errors. 
In addition, the high sensitivity of the pyeloureteral peristaltic 
machinery to disturbance affecting the structural or functional 
integrity of its components also contributes to the high incidence 
rate of urinary tract obstruction.
Introduction
Congenital obstructive nephropathy is the principal cause of renal 
failure in the pediatric population. Compared to adults, urinary tract 
obstruction in children is particularly damaging due to the perma-
nent impairment inflicted on the maturing kidneys. If left untreated, 
congenital obstructive nephropathy can lead to renal failure and even 
death.1 Congenital obstructive nephropathy is not only a devastating 
disease, but also a very common one. Hydronephrosis is found in 
antenatal screening at 1:100 with about 1 in 500 being clinically 
significant, making it the leading cause for renal failure in the 
pediatric population.2 There are different types of obstructive neph-
ropathy based on the location of the obstruction and/or the cause of 
the obstruction. Obstruction at the junction between the ureter and 
the renal pelvis is called Ureteropelvic Junction (UPJ) obstruction, 
which usually presents as hydronephrosis without obvious dilatation 
of the ureter (hydroureter). UPJ obstruction is estimated to occur 
in one out of 1,000–1,500 new births. Obstruction at other levels, 
such as ureterovesical junction (UVJ) and bladder outlet are also 
common. Obstruction in the urinary tract, in a strict sense, describes 
the presence of a physical blockage to the urine flow. However, 
the word “obstruction” is also used to describe the failure of urine 
transport from the kidney to the external environment regardless of 
the causes. The word “obstruction” is used in this manuscript in its 
broader sense to describe the physical blockage (physical obstruc-
tion) of the urinary tract and functional failure in urine transport 
(functional obstruction).
Experimental surgical animal models for obstructive nephropathy 
have been very useful in determining the pathologic impacts of the 
obstruction but less informative about the molecular and cellular 
lesions causing the disease.3-12 Despite this progress, the genetic or 
environmental determinants in most human patients with congenital 
defects in the kidney and the urinary tract are not known. In addition 
to familial cases, strong genetic determinants in congenital kidney 
and urinary tract defects were reported by a number of studies in 
seemingly sporadic cases.13-15 For example, Feather et al. found that 
there is a 30–50 fold increased incidence of vesicoureteral reflux in 
first-degree relatives of probands, compared with the general popu-
lation.14 The strong genetic component in congenital kidney and 
urinary tract defects demands more studies in the genetic factors and 
pathways involved in the pathogenesis of these devastating diseases. 
Mouse models, both genetically engineered and naturally occurring, 
have been making and will continue to make major contributions 
to these studies. Pathological consequences of congenital obstructive 
nephropathy have been described in detail from both human and 
animal studies for decades.16-21 The molecular and cellular lesions 
causing congenital urinary tract obstruction only started to come 
to light in recent years. Results from both genetically engineered 
and spontaneously occurring mouse models have revealed a high 
degree of heterogeneity in the origins of obstructive nephropathy 
and the developmental processes where most of the disease-causing 
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Urinary tract development and diseases
deleted in the MM and UM (Fig. 2F–I). The blood urea nitrogen 
(BUN) level in the mutants is on average more than 10 times higher 
than that of the controls. All mutants died of renal failure within 3 
weeks after birth.
Calcineurin is Required for the Development of the 
Pyeloureteral Peristaltic Machinery
We further showed by polymer molding that the mutant urinary 
tract is not physically obstructed. Instead, the pyeloureteral peristalsis 
is defective in the Pax3-CreT/+; Cnb1lox/lox mutants, leading to failure 
of urine transfer and functional obstruction.26,29 A key reason for 
the functional obstruction is the defective development of the renal 
pelvis and smooth muscle along the urinary tract. The mutants fail 
to form the funnel-shaped muscular structure of the renal pelvis that 
is important for normal peristalsis (Fig. 3A and B). The defective 
development of the renal pelvis is, in turn, caused by reduced prolif-
eration of the smooth muscle cells and their progenitors lining the 
developing renal pelvis. Ki67 staining revealed a reduction of prolif-
eration in the mesenchymal cells with calcineurin deficiency but not 
in the epithelium that retains calcineurin activity (Fig. 3C and D). 
anomalies occur.22 Continuing 
advances in mouse genetics and 
genomics will no doubt speed up 
the identification of the genetic 
factors and pathways involved in 
the pathogenesis of obstructive 
nephropathy.
Loss of Calcineurin in the 
Metanephric and Ureteric 
Mesenchyme causes Congenital 
Obstructive Nephropathy
Our interest in congenital 
obstructive nephropathy originated 
from the study of the calcineurin 
mutant mice. Calcineurin is a 
Ca2+-dependent serine/threonine 
phosphatase composed of a cata-
lytic subunit, CnA and a regulatory 
subunit, CnB (Fig. 1). CnB has 
a ubiquitously expressed isoform 
(Cnb1) and a testis-specific isoform 
(Cnb2). The regulatory subunit 
of calcineurin is indispensible for 
calcineurin activity.23,24 Thus inac-
tivation of Cnb1 in non-testis cells 
will render those cells deficient for 
calcineurin function.25 The NFATc 
(Nuclear Factor of Activated T 
Cells) transcription factors are the 
most extensively studied calcineurin 
substrates. They appear to be the 
major regulator of transcription 
downstream of Ca2+/Calcineurin 
signals.24 NFATc proteins reside in 
the cytoplasm in resting cells. Upon 
activation by an increase in intracel-
lular Ca2+, calcineurin dephosphorylates the NFATc proteins. This 
dephosphorylation exposes the concealed nuclear localization signals 
of the NFATc proteins, leading to translocation from the cytoplasm 
to the nucleus. Once in the nucleus, the NFATc proteins form NFAT 
transcription complexes with their nuclear partners to control the 
transcription of target genes.
In an earlier study, we used a Pax3-Cre transgene to direct the 
deletion of a loxP-flanked Cnb1 allele and serendipitously created a 
model for congenital obstructive nephropathy.26 The Pax3-Cre trans-
gene (Pax3-Cre) was originally generated to direct the recombination 
of loxP sites in neural crest cells and other tissues.27 Our analyses 
of mice carrying the Pax3-Cre transgene and the ROSA26RLacZ 
(ROSA) allele28 revealed that, within the urinary system, this trans-
gene is expressed specifically in the metanephric mesenchyme (MM) 
and ureteric mesenchyme (UM) derived tissues (Fig. 2A–E), but not 
in ureteric bud (UB) derived tissues. Especially, the smooth muscle 
cells of the renal pelvis and ureter (mesenchymal derivatives) have 
strong Cre expression as evidenced by the strong β-galactosidase 
activity in these cells (Fig. 2B–E). We unexpectedly discovered severe 
hydronephrosis in mutant mice (Pax3-CreT/+; Cnb1lox/lox) with Cnb1 
Figure 1. The Calcineurin-NFAT signaling pathway. Calcineurin is a calcium-dependent serine-threonine phos-
phatase. Calcineurin has a catalytic subunit “A” and a regulatory subunit “B”. Both of these subunits are 
indispensible for calcineurin activity. The activity of calcineurin can be inhibited by a number of intrinsic and 
pharmacological inhibitors, such as Cyclosporin A (CsA) and FK506. The increase in cytoplasmic calcium level 
can be triggered by many factors, including the activation of a diverse set of cell surface receptors, ion channels 
and even gap junctions. Intracellular calcium increase leads to the activation of calcineurin. Activated calcineurin 
dephosphorylates its substrates, including the NFATc transcription factors. The dephosphorylated NFATc proteins 
translocate from the cytoplasm to the nucleus to regulate the transcription of their target genes. The regulation 
of transcription by NFATc proteins requires nuclear partners (NFATn). These nuclear partners can be different 
for different target genes and in different cells. These nuclear partners are usually activated by a different set of 
receptors on the cell surface.



















Urinary tract development and diseases
The renal pelvis is critical for normal urine transfer in at least three 
ways. First, constriction of the junction between the renal pelvis and 
the ureter (ureteropelvic junction, UPJ) can lead to obstruction to 
the urine flow. Second, it has been proposed that the pacemakers for 
pyeloureteral peristalsis reside in the renal pelvis.30 These pacemaker 
cells are thought to be specialized smooth muscle cells that control 
the initial contraction of the smooth muscles lining the urinary 
tract. Third, the contraction of the funnel-shaped muscular structure 
of the renal pelvis provides the strong initial thrust that effectively 
propels urine down the ureter from the pelvicocaliceal space inside 
the kidney. Spontaneous peristalsis was observed in pyeloureteral 
complexes removed from the Pax3-CreT/+; Cnb1lox/lox mutants, 
suggesting that the pacemaker cells were still present in the mutants 
for the initiation of peristalsis. As revealed by polymer molding of 
the urinary tract in the mutants, physical constriction of the UPJ 
was not observed. Thus defective development of the “powertrain” 
for peristalsis (the renal pelvis and smooth muscle along the 
urinary tract) in the Pax3-CreT/+; Cnb1lox/lox is the major cause 
for the ineffective urine transfer and functional obstruction of 
the urinary tract.26
Interaction of Signaling Pathways in Urinary Tract 
Development
Since not all tissues and cells with Cnb1 deletion have reduced 
proliferation, we believe that calcineurin is not simply serving as 
a generic proliferation regulator in the MM and UM. Instead, it 
functions as a key factor in the mesenchyme for the interpretation 
of signals that originate in the UB-derived epithelium. A number 
of factors have important functions in the UB derivatives for 
urinary tract development.22 Among these factors, Shh commu-
nicates with its receptor Ptch in the mesenchyme to regulate 
smooth muscle differentiation.31 The deletion of Shh in the UB 
derivatives leads to defective smooth muscle development and 
obstructive nephropathy. In addition, Dlgh1 is expressed strongly 
in the epithelium, though it also has expression in the mesen-
chyme. Its inactivation results in a range of urogenital defects, 
including urinary tract smooth muscle defects and obstructive 
nephropathy.32,33 Since many signaling pathways directly or 
indirectly induce calcium increase in the target cells, it will not be 
surprising to see that the calcineurin signaling is embedded in a 
more complex signaling network and is constantly being modified 
by other interacting signals. The Renin-Angiotensin system (RAS) 
Figure 3. Inactivation of Cnb1 in the metanephric and ureteric mesenchyme 
disrupts the development of the pyeloureteral peristaltic machinery. (A and B) 
are hemi-sected control (A) and mutant (B) kidneys. The white arrows point to the 
UPJ. (C and D) are sections of the developing renal pelvic wall of control (C) and 
mutant (D) immunostained with a Ki67 antibody. The controls have significantly 
more proliferating mesenchymal cells along the developing renal pelvic wall. PP: 
papilla. M: mesenchymal derivatives. UT: urothelium. Modified from Figures 5 
and 7 from ref. 26 with permission.
Figure 2. Inactivation of Cnb1 in the metanephric and ureteric mesenchyme 
causes congenital obstructive nephropathy. (A–E) are samples from P1 
Pax3-CreT/+, ROSAT/+ mice. In the kidney proper, LacZ expression (blue, 
reflecting the Cre expression) is evident in the glomeruli and tubules that are 
MM-derived but not in the collecting duct system originated from the UB (A). 
The black arrow in (B) points to the developing glomeruli. The open arrow 
points to one of the UB branches. In the developing renal pelvic region, the 
connective tissues, the smooth muscle layers (SM) and the adventitia (AD) of 
the urinary tract express LacZ while the UB-derived urothelium (UT) remains 
LacZ-negative (C–E). U: ureter; PP: Papilla. The SM layers in the developing 
renal pelvic wall are illustrated by αSMA staining on a wild-type newborn 
sample of the same area (D). LacZ is also selectively expressed in the SM 
layers in the ureter but not in the stratified transitional epithelium (E). Mutants 
(Pax3-CreT/+, Cnb1lox/lox) have severe hydronephrosis and erosion of the 
kidney parenchyma (G and I compared with F and H. Samples G and H 





















Urinary tract development and diseases
genetic mutation in the cph (congenital progressive hydronephrosis) 
mice.43 cph was first discovered as a spontaneous, autosomal reces-
sive trait in the 1970s.44,45 Since these mutants were thought to 
have renal cysts, they were named jpk for Juvenile Polycystic Kidney 
until a later study found that the pathologic changes were cystic 
renal dysplasia caused by progressive hydronephrosis secondary to 
UPJ obstruction.45 We performed a thorough analysis of the urinary 
system in the cph mutants and found that besides UPJ obstruction, 
some of them also have UVJ obstruction and hydroureter.43 Based 
on polymer molding, there is no physical blockage of the urinary 
tract, suggesting another example of functional obstruction. Early 
postnatal hydronephrosis usually progresses rapidly, leading to loss of 
renal function and death (Fig. 4A–F). To identify the causative muta-
tion, we performed genetic mapping that located the cph mutation to 
a 0.7 Mb chromosomal region on mouse chromosome 15 (Fig. 4G). 
There were still approximately 30 known genes and predicted open 
reading frames in this interval.43
After studying the genes within the suspected chromosomal 
interval, we discovered that the distribution of the water channel 
protein Aqp2 was altered in the mutants. Aqp2 functions as a water 
channel to reabsorb water from the collecting duct lumen back to 
the interstitium. While Aqp2 was predominantly distributed on 
the apical membrane of the principal cells in the collecting ducts 
is known to be involved in renal injury in congenital obstructive 
nephropathy. RAS, however, has a constructive role during urinary 
tract development.34,35 Mutations in a number of RAS component 
genes cause congenital anomalies of the kidney and urinary tract 
(CAKUT).36-42 Although the broad effect of RAS in blood pres-
sure control and regulation of the ability to concentrate urine may 
contribute to the observed renal pathological changes, evidence 
suggests that direct function of RAS in the ureteral SM differentia-
tion plays an important role.38 In fact, a number of studies suggest 
that RAS can induce activation of calcineurin. Our recent studies 
indicate that transgenic activation of Nfatc1 in the urinary tract also 
leads to severe developmental anomalies including hydroureters and 
hydronephrosis (Wang and Chen F, unpublished data). It is possible 
that within the urinary system, RAS activates calcineurin to regulate 
Nfat-mediated transcription for proper urinary tract development 
and differentiation.
Genetic Mutations causing Congenital Obstructive 
Nephropathy
Besides genetically engineered mice, the identification of unknown 
causative mutations in mice with congenital obstructive nephropathy 
is another way to reveal the genetic determinants in this disease. One 
example of such forward genetic studies is the identification of the 
Figure 4. Genetic mapping of the cph mutants with congenital obstructive nephropathy. (A–C) The mutants have unilateral or bilateral hydronephrosis and 
hydroureter (arrow). (D) The BUN level in the mutants (P5-P16) is dramatically increased. (E and F) Kidney sections from P14 control and mutant littermates 
stained with H&E. (G) Physical map of relevant portions of mouse chromosome 15. Our genetic mapping efforts locate the cph locus to the chromosomal 
interval of about 0.7 Mbp, defined by the microsatellite markers C15LD6 and C15LD5. The black triangle indicates the chromosomal location of Aqp2. 
Modified from Figures 1 and 3 from ref. 43 with permission.



















Urinary tract development and diseases
highly conserved in all vertebrate species. The loss of this 
key  phosphorylation due to the cph mutation results in the 
loss of apical trafficking of the Aqp2 protein. The direct 
physiological effect of this trafficking defect is in urine 
concentration. As a consequence, the cph mutants produce 
a high volume of hypotonic urine and show classic char-
acteristics of Nephrogenic Diabetes Insipidus, including 
insensitivity to vasopressin.43 The cph mutants were first 
described as having polycystic kidney disease, before it 
was later found to have progressive hydronephrosis and 
obstructive nephropathy instead. Our study shows that the 
underlying cause is in Aqp2 distribution and urine concen-
tration. They actually have Nephrogenic Diabetes Insipidus 
and the drastic increase of urine output overwhelms the 
urine transfer machinery, secondarily causing hydroneph-
rosis. Many diseases share similar structural anomalies and 
present with similar symptoms, but accurate diagnosis can 
only be made by revealing the underlying molecular and 
cellular lesions.
Diverse causes of Obstructive Nephropathy
Our ongoing research involves other urinary tract 
disease models that are either spontaneously occurring 
murine mutants, transgenic mice with alterations in 
specific genes, or transgenic mice with specific ablation of 
progenitor cells involved in the development of the urinary 
system. As we learn from our own studies and studies from 
many other laboratories, obstructive nephropathy can be 
caused by a diverse set of factors targeting different parts 
of the urinary system.22,46 Most of the known causes affect 
the development of the lower urinary tract. These include 
the underdevelopment of the pelvis and the malformation 
of the ureteric smooth muscle as we see in the calcineurin 
mutants. Defects in the ureteric epithelium can directly 
or indirectly affect the pyeloureteral peristalsis, leading to 
obstruction. The joining of the ureter to the bladder is a 
complex process where errors are prone to occur.47-49 As 
seen in the cph mutants, in addition to problems in the 
lower urinary tract, anomalies in the kidney proper can 
also lead to physiological changes that eventually break 
down the urine transfer machinery, causing obstruction. 
The essential pyeloureteral peristalsis is a process that requires high 
structural and functional integrity of all of its components, making 
it sensitive to disturbances caused by genetic and environmental 
factors. Perhaps this sensitivity of pyeloureteral peristalsis to such 
disturbances and the complexity in the formation of the junctional 
complexes along the urinary conduit set the stage for the high inci-
dence of congenital urinary tract obstruction (Fig. 6).
A Systematic View of the Development of Urinary Tract 
Obstruction
Development of the urinary tract requires the integration of 
progenitor populations with diverse embryonic origins (Fig. 6). 
The majority of the nephron components are from the MM within 
the intermediate mesoderm. The UB contributes to the ureteric 
epithelium and the collecting duct epithelium.50,51 The tailbud-
derived mesenchyme gives rise to the UM which, in turn, produces 
in control mice, its apical accumulation was completely lost at all 
levels of the collecting duct in all homozygous mutants (Fig. 5A 
and B). At that point, we could not be certain if the observed 
difference in distribution was merely a pathological change due to 
obstructive nephropathy or was in fact the cause for the renal defects. 
We thus examined the distribution of Aqp2 in the principal cells of 
the Pax3CreT/+; Cnb1lox/lox mutants that also have severe congenital 
obstructive nephropathy.26 The distribution of Aqp2 was not signifi-
cantly changed in the Pax3CreT/+; Cnb1lox/lox mutants despite overt 
collecting duct dilatation (data not shown), suggesting that absence 
of Aqp2 apical accumulation was not simply a secondary effect of the 
congenital obstructive nephropathy.
By sequencing the Aqp2 gene, we discovered a mutation in 
nucleotide 767 in the fourth exon of Aqp2 in the mutants (Fig. 
5C). The C-T change in codon 256 led to a Ser to Leu substitution 
in the protein. This S256 is actually a phosphorylation site and is 
Figure 5. A mutation in Aqp2 disrupting its trafficking causes urine concentration defect 
and obstructive nephropathy. (A and B) Immunostaining of the collecting ducts in the 
outer medulla shows apical accumulation of Aqp2 in the controls (A) but a diffuse stain-
ing with no apical accumulation in the mutant (B). (C) Sequence of the fourth exon of 
Aqp2 reveals the C-T substitution at nucleotide 767 in the homozygous mutants, while 
the heterozygotes have both C and T represented at position 767. This substitution 
results in a Ser to Leu change at amino acid 256 in the cytoplasmic tail of the Aqp2 





















Urinary tract development and diseases
Figure 6. Urinary tract development requires the integration of diverse progenitor cell populations and the formation of multiple junctions. Nephron compo-
nents, excluding the collecting ducts, are derived from the MM within the intermediate mesoderm. The collecting duct and the ureteric epithelium are derived 
from the UB. The tailbud-derived mesenchyme gives rise to the UM that in turn produces the smooth muscles and other mesenchymal derivatives along the 
ureter and along the ureter. While the vesical (bladder) epithelium is from the hindgut endoderm, the vesical mesenchyme appears to arise from tailbud-
derived mesenchyme. The lineage origin of the urethral mesenchyme is not entirely clear, but the urethral epithelium is also derived from the same hindgut 
endoderm that gives rise to the vesical epithelium. The origin of the renal capsule is less clear but appears to be distinct from the other structures within the 
urinary system. The use of different colors is for the distinction of tissues with different embryonic origins. The different colors used for the UM and vesical mes-
enchyme (both from the tailbud-derived mesenchyme) reflect the fact that they develop as separate structures before being joint together later in development. 
The entire urinary tract is also highly innervated. The integration of these diverse progenitor populations also involves the formation of junctional complexes, 
especially at the UPJ and UVJ. Any disruption of the regulation of the integration could lead to urinary defects, including urinary tract obstruction.
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to position closer to the middle than normal. This sets up an unstable 
state that any slight variation may cause fusion of the MM from 
both sides and, subsequently, the formation of horseshoe kidneys. 
The ascent of the horseshoe kidneys tends to be impeded by crossing 
blood vessels, causing subsequent problems such as hydronephrosis 
and hydroureter. However, if no fusion occurs, the left and right 
kidneys may develop relatively normally despite their unusually 
close proximity to each other. Therefore, very slight and random 
variations may separate a rather healthy state and a potentially very 
morbid state.
Conclusions
Genetically engineered and naturally occurring murine models are 
powerful tools in the study of congenital obstructive nephropathy. 
With the advance of mouse genetics and genomics, the use of these 
tools will certainly expand. While we now have a much better under-
standing of urinary tract development and the causes of congenital 
urinary tract obstruction than a decade ago, identifying the cause 
and determining the most suitable treatment for a particular patient 
remain a challenge for basic researchers and clinicians to tackle for 
years to come.
Conference Questions and Answers
Dr. Paul Austin, Associate Professor of Surgery, Washington 
University School of Medicine: When do the cph mutants die?
Dr. Chen: Usually they die within the first month.
Dr. Austin: Are they normal at birth?
Dr. Chen: Yes, at birth they look normal. The hydronephrosis 
usually becomes obvious within the first week of life.
Dr. Eduardo Slatopolsky, Joseph Friedman Professor of Medicine, 
Washington University School of Medicine: You indicate that polyuria 
will induce breakdown of the peristaltic machinery and that produces 
renal insufficiency. Most patients with diabetes insidious do not have 
a decrease in renal function. Why is it different in the mice?
Dr. Chen: Patinents with diabetes insipidus can have hydroneph-
rosis and hydroureter, if they don’t take medication and drink too 
much. Mice drink as much as they want and are not medicated. It is 
possible that polyuric mice are more prone to hydronephrosis than 
polyuric humans. In any case, I think the breakdown of the peri-
staltic machinery induced by polyuria is the most likely explanation 
for the functional obstruction in the cph mice.
Dr: Austin: I would agree with you because we see clinically 
that pediatric patients with polyuria can overwhelm their bladder 
capacity. This results in a functional obstruction that can cause renal 
scarring. In many of those kids, we recommend over night Foley 
drainage to decompress the bladder and prevent elevated pressure 
from the functional obstruction.
Dr. Chen: Right. Thanks.
Dr. Slatopolsky: You showed that a mutation in Aqp2 disrupting 
its trafficking causes urine concentration defect and obstructive neph-
ropathy. Did you have the opportunity to study the osmolality of the 
medulla of those animals. If you don’t have a hypertonic medulla, 
even if you have a working aquaporin, you cannot concentrate the 
urine, and you get polyuria. You need both a functional aquaporin 
and you need hypertonic medulla.
Dr. Chen: That is a good point. We did not measure the 
osmolality of the mutant medulla. However, one would expect 
the smooth muscle and other mesenchymal derivatives along the 
ureter and along the ureter.52 While the vesical (bladder) epithelium 
is from the hindgut endoderm, the vesical mesenchyme appears to 
arise from tailbud-derived mesenchyme.52 The lineage origin of the 
urethral mesenchyme is not entirely clear, but the urethral epithelium 
is also derived from the same hindgut endoderm that gives rise to the 
vesical epithelium.53 The temporal and spatial integration of these 
diverse progenitor populations requires precise control by a number 
of signaling pathways. Any disruption of these signaling pathways 
could affect the integration, leading to a wide range of renal defects, 
including agenesis, hypoplasia, supernumerary ureter, hydroureter, 
hydronephrosis and others. Presence of multiple types of defects in 
the kidney and the urinary tract is described as CAKUT (congenital 
anomalies of the kidney and urinary tract).54,55 On one hand, the 
term CAKUT reflects the fact that defects in the urinary system 
can have very different phenotypes. It may also encourage urologists 
and nephrologists to work together to tackle these complex diseases 
that tend to affect both the kidney and the lower urinary tract. 
Some investigators, however, dislike the term CAKUT because of 
the perceived risk of blurring the pathological distinction of distinct 
disease subtypes. In any case, it is clear that disturbance during 
embryogenesis can affect multiple interconnecting processes for 
the development of the urinary system, causing a wide spectrum of 
defects in the kidney and urinary tract. Even if the primary molecular 
and cellular lesions initially affect only part of the system, the struc-
tural and functional integration of the system eventually leads to 
disruption of the development and integrity of other parts of the 
urinary system. Thus, a systematic view of the development of the 
urinary system is necessary even when a particular defect, such as 
urinary tract obstruction, is being studied.
Phenotypic Variations in Congenital Urinary Tract Defects
It is common to see phenotypic variations in human patients and 
animal models with urinary tract defects. We have seen variations 
among affected individuals of the same genotype or even between 
the left and right sides of the same individual. Variations are seen 
in any organ systems, but some unique characters of urinary system 
may have made it more prone to extreme variations. I will use two 
hypothetical examples here to better illustrate this point (Fig. 7). 
In the first example, a genetic defect slows UB budding to a degree 
that the UB barely reaches the MM just in time to prevent its apop-
tosis. Other problems associated with this mutation then lead to the 
development of urinary tract obstruction. However, any additional 
disturbance, including intrinsic variations or random extrinsic factors, 
may cause an additional minor delay in UB outgrowth, causing the 
failure of the UB to reach MM before its degeneration and leading to 
renal agenesis. This is similar to a scenario where you are running late 
to catch a train. You may be lucky to get on it at the last second, or 
your taxi to the station may hit one red light too many and you miss 
it all together. The outcomes are very different (a train journey or 
no train journey), but result from what could be considered a minor 
difference in timing (one red light too many resulting in a delay of 
seconds). By analogy, in kidney and urinary tract development, what 
could be considered a minor quantitative difference (slower UB 
outgrowth, for example) may be translated into qualitatively distinct 
outcomes (renal agenesis or a kidney with urinary tract obstruction) 
in affected individuals. In another hypothetical example, abnormal 
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Figure 7. Quantitative differences can be translated into 
qualitatively distinct outcomes in urinary tract develop-
ment, contributing the phenotypic variations. (A) In a 
hypothetical scenario, a genetic defect affects UB budding 
to a degree that the UB barely reaches the MM just in time 
to prevent its apoptosis. Other problems associated with 
this mutation then lead to the development of urinary tract 
obstruction. Any additional disturbance may delay the UB 
outgrowth further, causing the failure of the UB to reach 
MM before its degeneration and leading to renal agen-
esis. This is similar to a scenario (depicted in B) where 
you are running late to catch a train. You may be lucky to 
get on it at the last second, or your taxi to the station may 
hit one red light too many and you miss it all together. In 
another hypothetical example (C), abnormal intermediate 
mesoderm patterning causes the MM from both sides to 
position closer to the midline than normal. The left and 
right kidneys may develop relatively normally despite their 
unusual positions. However, the close proximity of the MM 
from both sides sets up an unstable state that any slight 
variation may cause MM fusion and the occurrence of 
horseshoe kidneys that tend to be obstructed. Therefore, 
very slight and random variations may separate a rather 
healthy state and a potentially very morbid state. 
that the Aqp2 defect would affect the medullary 
gradient.
Dr. Jianghui Hou: Assistant Professor of Medicine, 
Washington University School of Medicine Does the 
lower urinary tract have transport function?
Dr. Chen: As you know, aquaporin 2 is expressed 
in the collecting duct principal cells and serves as a 
channel for water transport. However, in the lower 
urinary tract, namely the ureter and the bladder, the 
expression of Aqp2 is insignificant, if there is any 
at all. In fact, we looked for Aqp2 expression in the 
ureter and bladder using immunehistochemistry and 
found no positive staining. We doubt that aquaporin 
2 has any significant water reabsorptive function in 
the lower urinary tract.
Dr. Jochen Lennerz, Molecular Genetic Pathology 
Fellow, Anatomic & Molecular Pathology, Washington 
University School of Medicine: You haven’t talked 
about the innervations of the urinary tract. It has 
been speculated that nervous system abnormalities 
might be a cryptic cause of obstruction. Can you talk 
about the neural control of peristalsis? The reason I 
ask is because calcineurin has important functions in 
the nervous system and is a target of a class of drugs.
Dr. Chen: That is a good question. One of the 
first things we did when we began the calcineurin was 
to examine the ureters from mutants and controls 
histologically looking for differences in neural inner-
vation. We saw no structural differences. However, 
it is much harder to test functionally. Certainly, the 
nerves are there and must be doing something. On 
the other hand there are experiments showing that 
the peristaltic process is primarily a myogenic. In the 
movie I showed in the talk, pyeloureteral peristalsis 
happened in the isolated urinary system without 
any innervation in the dish. In fact, you can add 
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neural blockers to the dish to block nerve activity without affecting 
peristalsis.
There is no innervation following kidney and ureter transplan-
tation, at least not in the initial stage. However, the ureter still 
functions.
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